FINRA aggregates and reports the short positions the brokers provide to them. The SEC aggregates and reports the failure to deliver information the brokers report to them. It isn't lies, it's the facts. The lies are the con artist pumpers who use "shorty" as an excuse to explain the inevitable decline in share price when they sell their holdings.
I swear I’ll never use the phrase “you can’t make this stuff up” ever again after being on the OTC. Apparently you can.
Recent BGLC News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/14/2026 09:20:27 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:25:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 06:30:11 PM
- BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform • GlobeNewswire Inc. • 03/11/2026 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:35:38 PM
- BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman • GlobeNewswire Inc. • 02/23/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:10:29 PM
- BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market • GlobeNewswire Inc. • 01/28/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/30/2025 06:30:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 10:20:34 PM
- BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™ • GlobeNewswire Inc. • 12/03/2025 01:45:00 PM
- BioNexus Gene Lab Shares Jump After Securing $500 Million Equity Facility • IH Market News • 12/02/2025 03:34:38 PM
- BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization • GlobeNewswire Inc. • 12/02/2025 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/02/2025 01:00:50 PM
- BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene • GlobeNewswire Inc. • 12/01/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 10:21:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 01:00:39 PM
- BioNexus Gene Lab Shares Surge on Strategic MRD Testing Partnership • IH Market News • 11/12/2025 03:24:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 01:32:04 PM
- BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization • GlobeNewswire Inc. • 11/12/2025 01:00:00 PM
- BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities • GlobeNewswire Inc. • 11/10/2025 01:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/07/2025 09:32:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2025 12:00:49 PM
- BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc. • GlobeNewswire Inc. • 10/20/2025 12:00:09 PM
